Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Immunocore Holdings PLC Sponsored ADR (IMCR) vs Cyclerion Therapeutics, Inc. (KRSA)

Immunocore Holdings PLC Sponsored ADR and Cyclerion Therapeutics, Inc. are both Biotechnology companies. Immunocore Holdings PLC Sponsored ADR and Cyclerion Therapeutics, Inc. are of similar size ($1.7B and $1.6B). Cyclerion Therapeutics, Inc. grew revenue faster over the last twelve months: 30.8% against 21.0%. Cyclerion Therapeutics, Inc. has the higher net margin (0.00% vs −4.20%) and the lower return on invested capital (−115.4% vs 0.00%). Across the 18 metrics below, Immunocore Holdings PLC Sponsored ADR leads on 10 and Cyclerion Therapeutics, Inc. on 8.

Valuation

Metric IMCR KRSA Biotechnology median
P/E n/m n/m 7.88
P/S 3.64 9.08 11.47
P/B 3.73 3.70 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 2.62 8.41 10.73
Earnings yield (1.17%) (37.47%) (28.84%)
Free cash flow yield (2.63%) (24.02%) (23.03%)

Profitability

Metric IMCR KRSA Biotechnology median
Gross margin 98.90% 100.00% 65.16%
Operating margin (5.24%) 0.00% 0.00%
Net margin (4.20%) 0.00% 0.00%
Free cash flow margin (9.55%) 0.00% 0.00%
Return on equity (4.47%) (98.22%) (57.72%)
Return on assets (1.64%) (82.29%) (49.22%)
Return on invested capital 0.00% (115.40%) 0.00%

Growth

Metric IMCR KRSA Biotechnology median
Revenue growth (TTM) 20.95% 30.77% 5.64%
EPS growth (last fiscal year) 30.39% 8.26% —
Revenue growth, 5-year CAGR 59.57% (14.38%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMCR KRSA Biotechnology median
Debt to equity 0.94 0.00 0.00
Current ratio 4.47 0.82 4.73
Net debt to EBITDA 11.19 0.65 0.96

Dividend

Metric IMCR KRSA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IMCR KRSA Biotechnology median
Market cap 1.61b 1.69b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack